Emergent up on gaining commercial rights for Hikma's opioid overdose treatment

Emergent BioSolutions

14/01/2025 13:48

** Shares of drugmaker Emergent BioSolutions  EBS.N  rise
~2.9% to $9.68 premarket
    ** Emergent says it gained exclusive commercial rights to
Hikma Pharmaceuticals'  HIK.L  opioid reversal nasal spray,
Kloxxado
    ** Kloxxado rapidly reverses or blocks the effects of
opioids, restoring normal respiration, especially when given
within minutes of the first signs of an overdose
    ** Under the terms of the agreement, Hikma will continue to
manufacture the nasal spray, while Emergent will handle
distribution
    ** Up to last close, EBS up more than four-fold in the last
12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))